Cadila Healthcare Ltd has announced that Zydus Cadila has received its very first approval from USFDA to market Atenolol, an anti-hypertensive drug, in the US market.
ZyCoV-D is a three-dose vaccine administered intradermally.
Zydus Cadila Healthcare Ltd on Tuesday said it has received approval from the French regulatory agency, AFSSAPS, to market Sertraline capsules 25 mg and 50 mg, in the French market.
Cadila Healthcare Ltd board approved amalgamation of German Remedies Ltd, Recon Healthcare Ltd, Zydus Pathline Ltd & Zoom Properties Ltd with the company.
While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
Three COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India.
The teams were from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad.
Cadila Healthcare Ltd said on Thursday, said German Remedies, a part of the Zydus Group, has launched Fludara Oral (Fludarabine) in the Indian market for the treatment of chronic lymphocytic leukemia.
The vaccine candidate -- 'Covaxin' -- is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
According to government sources, the matter was discussed by the national expert group on vaccine administration for COVID-19 in its last meeting held on August 22.
Cadila Healthcare Ltd has received tentative approval from US FDA to market its antibiotic, Gatifloxacin tablets, 200 mg and 400 mg, in the US market.
Efforts are being ramped up for massive production of vaccines and make them available in the shortest possible time, a top government official said on Wednesday, stressing that India currently has a promising pipeline of four-five Covid-19 vaccine candidates, while three have already been approved for emergency use.
Cadila Healthcare Ltd has received tentative approval from the USFDA to market Pravastatin Sodium Tablets in the US market.
Cadila Healthcare to seek nod for amalgamation
Cadila Health, to merge with German Remedies
Cadila Healthcare Ltd on Monday said it has received tentative approval from the US FDA to market Levofloxacin tablets of 250 mg, 500 mg and 750 mg in the US market.
The aim of the mission is to accelerate the development of at least six vaccine candidates and ensure that they are licenced and introduced in market for emergency use at the earliest.
Dr V K Paul, Member (Health) Niti Aayog, who also chairs the national expert group on COVID-19 vaccine administration, said the government attaches 'great importance to this offer of partnership from a very special friend to this nation'.
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said.
'Please don't read something which is not there in DG, ICMR's letter. The intent of the letter is only to expedite duly approved clinical trials without compromising on security and safety concerns'
Cadila Healthcare Ltd has posted a net profit of Rs 39.43 crore for the second quarter ended September 30, 2003, compared to Rs 30.28 crore recorded in the same period last fiscal.
'We must not compromise with the standard, the quality. We don't need to be the first to launch a drug but what we need is a Made in India vaccine that the entire world can rely on'
With the government asking the companies to operate with only 50 per cent staff strength, and exports dipping to almost zero, the truck and bus drivers idling at the petrol pump say they hardly have any work now. At a petrol pump on the deserted Bavla-Changodar highway near Ahmedabad in Gujarat, several trucks and buses are neatly parked in a row.
The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS in New Delhi on Thursday, with Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.
The health ID will contain information about medical data, prescriptions and diagnostic reports and summaries of previous discharge from hospitals for ailments. The mission is expected to bring efficiency and transparency in healthcare services in the country.
'Pfizer India has submitted an application on December 4 to the DCGI seeking emergency use authorization for its COVID-19 vaccine in India'
The modalities of COVID-19 vaccine delivery, distribution and administration were discussed during the meeting.
The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology. The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry molecular instructions to make the protein in the body through a synthetic RNA of the virus.
'The prioritisation of groups for COVID-19 vaccine shall be based on two key considerations -- occupational hazard and risk of exposure to infection, and the risk of developing severe disease and increased mortality'
Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials.
German Remedies seeks nod for amalgamation with Cadila Healthcare
For India Inc, latest GDP figures signal a turnaround.
The ministry further stated that it was advisable to receive a complete schedule of the anti-coronavirus vaccine irrespective of past history of infection with COVID-19 as this will help in developing a strong immune response against the disease.
More than 2 million people have been diagnosed with coronavirus across the world, and the pharmaceutical industry is pulling out all stops to find potential treatments and vaccines for the global pandemic. According to the World Health Organization, there are now more than 70 potential vaccines under evelopment, with some already in clinical trials.
The vaccine candidate, ZyCoV-D, showed a "strong immune response" in animal studies, and the antibodies produced were able to completely neutralise the wild type virus, Zydus said. The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.
Armed with green nod and fund infusion, Gujarat govt getting ready to issue tenders to build infrastructure at the mega investment region
At present, there is no direct air connectivity between India and Myanmar.
As many as 24 special economic zone (SEZ) developers including Dr Reddy's Lab and Tata Consultancy Services have sought more time from the government to execute their projects.
Ajit Mishra, vice president, Research, Religare Broking, answers your stock market queries.
